Difference between revisions of "Sarcomatoid renal cell carcinoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "/abstract " to " ") |
Warner-admin (talk | contribs) m (Text replacement - "https://onlinelibrary.wiley.com/doi" to "https://doi.org") |
||
| Line 47: | Line 47: | ||
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://doi.org/10.1002/cncr.29503 Michaelson et al. 2015 (MGH 07-212)] |
|2007-2013 | |2007-2013 | ||
| style="background-color:#91cf61" |Phase 2 | | style="background-color:#91cf61" |Phase 2 | ||
| Line 60: | Line 60: | ||
===References=== | ===References=== | ||
| − | # '''MGH 07-212:''' Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 1;121(19):3435-43. Epub 2015 Jun 8. [https:// | + | # '''MGH 07-212:''' Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 1;121(19):3435-43. Epub 2015 Jun 8. [https://doi.org/10.1002/cncr.29503 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26058385 PubMed] NCT00556049 |
[[Category:Sarcomatoid renal cell carcinoma regimens]] | [[Category:Sarcomatoid renal cell carcinoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Renal cell carcinomas]] | [[Category:Renal cell carcinomas]] | ||
Revision as of 00:51, 17 September 2022
Section editor transclusions Note: these are regimens tested in histology-specific populations, please see the main RCC page for other regimens.
2 regimens on this page
2 variants on this page
|
Metastatic disease, first-line
Doxorubicin & Gemcitabine
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Haas et al. 2012 (ECOG 8802) | 2004-2007 | Phase 2 |
Chemotherapy
- Doxorubicin (Adriamycin) 50 mg/m2 IV push once on day 1
- Gemcitabine (Gemzar) 1500 mg/m2 IV over 30 minutes once on day 1
Supportive medications
- One of the following:
- Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting on day 2 or 3, given until day 10
- Pegfilgrastim (Neulasta) 6 mg SC once on day 2
14-day cycle for 6 to 9 cycles (cumulative doxorubicin dose of 300 to 450 mg/m2, depending on cardiac function)
References
- ECOG 8802: Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012 Jun;29(2):761-7. Epub 2011 Feb 6. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00068393
Gemcitabine & Sunitinib
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Michaelson et al. 2015 (MGH 07-212) | 2007-2013 | Phase 2 |
Chemotherapy
- Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
Targeted therapy
- Sunitinib (Sutent) 37.5 mg PO once per day on days 1 to 14
21-day cycles
References
- MGH 07-212: Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 1;121(19):3435-43. Epub 2015 Jun 8. link to original article PubMed NCT00556049